Egetis Therapeutics secures a US Fast Track Designation (FTD) for Emcitate for MCT8 Deficiency - Redeye
Redeye is encouraged by the news that Egetis Therapeutics has received an FTD from the US Food and Drug Administration (FDA) for its lead candidate Emcitate for the treatment of MCT8 Deficiency.
ANNONS
Redeye is encouraged by the news that Egetis Therapeutics has received an FTD from the US Food and Drug Administration (FDA) for its lead candidate Emcitate for the treatment of MCT8 Deficiency.